Trials / Completed
CompletedNCT02471469
Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
Personalizing Enzalutamide Therapy by Understanding the Relation Between the Decrease in the Expression Profile of a Panel of Preselected microRNAs, Tumor Related mRNAs and Treatment Response in Chemotherapy Naive Patients With mCRPC
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim is to show whether a reduction in tumor related mRNAs and a panel of selected miRNAS can be used to personalize enzalutamide therapy. Furthermore the aim is to explore the relation between drug exposure and the decrease in the selected biomarkers and treatment response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide, 160mg, 40 mg soft capsules, once daily | Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2019-02-13
- Completion
- 2019-08-01
- First posted
- 2015-06-15
- Last updated
- 2020-10-19
Locations
3 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02471469. Inclusion in this directory is not an endorsement.